David Su

🧬 New paper out in @Nature! We used CRISPR to selectively kill cancer cells based on a single-letter mutation in their RNA. The story I want to highlight: KRAS — one of the most notorious drivers of human cancer. A short thread on what we found 🧵

1/ Thrilled to share our new paper, out today in @Nature: "Non-invasive profiling of the tumour microenvironment with spatial ecotypes". Paper (open access): nature.com/articles/s4158…

it is hard to get @SKonermann to do media - she is a true lab rat - so I am excited for more of the world to hear from her directly!

📢 Abstract submissions are open for SAAS 2026! It's not too late to submit your exceptional work. 🗓 Deadline: April 1, 11:59 PM PST 🔗 Submit here: saas2026.exordo.com #SAAS2026 #AcademicSurgery @JSurgRes

@DrRoyHerbst @DartmouthCancer @GeiselMed Congrats @DrRoyHerbst!

I am honored and excited to announce that I will join the Dartmouth community in July as Director of the Dartmouth Cancer Center. Looking forward to continuing the important work of advancing cancer care, research, and patient impact. @DartmouthCancer @GeiselMed geiselmed.dartmouth.edu/news/2026/dart…

Dartmouth is so lucky to have you @DrRoyHerbst! Thank you for your 15 years of Thoracic Oncology and SPORE leadership at Yale! You have been such a wonderful mentor and supporter, we will miss you!!

@gogo_gopss @pennsurgery @WomenSurgeons @AmCollSurgeons @snhthm Congrats Gopika!!

Beyond honored and excited to be heading to @pennsurgery for residency! Words cannot describe how grateful I am for my mentors, family, and friends who helped make this possible! #MATCH2026 @WomenSurgeons @AmCollSurgeons

The highest honor bestowed within our organization, the Yale Cancer Center Lifetime Achievement Award, was presented to Dr. Mario Sznol @MSznol by @DrRoyHerbstYale. Dr. Sznol was recognized for 40+ years of extraordinary contributions to oncology. We are proud to celebrate his remarkable legacy. @SmilowCancer

Big thanks to @GDemaitre and @TheRobotReport for covering the launch of MedOS! 📄📷 We’re building the future of autonomous science and clinical assistance with an AI-XR-Cobot world model. Proud of the team! therobotreport.com/stanford-princ…

1/ When starting a🤖Whipple program, struggle is always balancing patient selection for safe completion vs⬇️volume w being selective. We asked if it was safe w being liberal w pt selection w a lower threshold to convert for non-progression. Results in🧵! sciencedirect.com/science/articl…

December Issue: HOXA13 overexpression is associated with poor prognosis in #ColorectalLiverMetastases @DavidSuMD ow.ly/WgzU50XQ0r4 @FlavioRochaMD @DrMikeCavnar @SKMaithel @HalletJulie @JulietOkoroh @TheNotoriousHPB @AradhyaNigamMD @SocSurgOnc

Ismail Ajjawi @YaleMed ’27 @YaleBreast presents data on premenopausal women with early-stage HR+/HER2– node-negative #breastcancer at #SABCS25 • Chemo use declined from 35%→24% • 72% omitted chemo, with no difference in 5-yr OS (98.1% vs 97.6%) Chemotherapy omission is rising without observed survival impact. Trials like OFSET will help define when omission is safe. @OncoAlert @SABCSSanAntonio @SmilowCancer @maryam_lustberg

🔥off the press🔥 Cholangiocarcinoma 2026: status quo, unmet needs and priorities @NatRevGastroHep doi.org/10.1038/s41575… 👉get the lastest, most comprehensive summary on cholangiocarcinoma 👏fantastic team effort! @myESMO @EASLedu @ILCAnews

‼️Proud to recognize Drs. Johannes Kratz & Jeroen Roose, Co-PIs on their proposal “Advancing Two-Hit Therapy Approaches for K-Ras Mutation Cancers,” selected by the Lopker Family Foundation from 30 proposals. Awarded $250K, this project unites @immunox & @UCSFCancer researchers💫

Amazing webinar! Thank you @MackenzAbraham @hillaryrjohnson Mitchell Won @j_broekhuis for taking the time to help surgical trainees prep for ABSITE. Videos & pdfs will be available on the @SSATNews website 📝 Become an @SSATNews member, contribute to the future of GI surgery! ⭐️

Honored to join international leaders in immunotherapy, including @Maker_MD, to publish this deep-dive on what’s possible next for TIL therapy. Engineered TIL, bispecific-enhanced expansion, and pre-TIL strategies are opening doors for the treatment of GI, hepatobiliary, lung, and other solid tumors. Proud to be part of this next era of cellular immunotherapy. 🚀 @UCSFSurgery @sitcancer @UCSFCancer

The top 10 people of 2025 @Nature who shaped science Recognizes Dr. Susan Monarez, the CDC Director who was "fired for holding the line on scientific integrity" nature.com/immersive/d415…

Let me ask an uncomfortable question. There are a lot of surgeons being trained who feel not comfortable performing open surgery. They won’t convert MIS to open because they just are not comfortable. HAVE WE SKIPPED THE MIS to open paradigm of training.

Excited to present the first major work after starting our lab at Stanford and the Arc this year: CRISPR-All, a unified genetic perturbation language for programming any major type of genetic perturbation simultaneously, in any combination, at genome scale, in human cells.